Naeem Arshad Chaudhri, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

None Reported

King Faisal Specialist Hospital & Research Center
Rank: Consultant
Years: 1995-present
King Faisal specialist Hospital & Research Centre
Rank: consultant
Years: 1995-Present
Al Faisal University, College of medicine
Rank: Full Professor
Years: 2010-Present

Outcome of second allogeneic bone marrow transplantation after myeloablative conditioning and its correlation with prognostic factors
Blood
Volume: 96,11
Date: 11 2000

Risk factors and clinical characteristics of hepatitis B virus reactivation post allogeneic stem cell transplantation in patients previously infected and immune to HBV.
Biology of blood and marrow transplantation.
Volume: 7,no 2
Date: 01 2001

Azithromycin in bronchiolitis obliterans complicating bone marrow transplant: a prliminary study.
Eur Respir J 2005: 490-493
Date: 01 2005

successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoitic stem cell transplant by early administration of a short course of methylprednisolone
Bone marrow Transplantation
Volume: Nov 5
Date: 11 2007

The challenge of risk stratification in acute myeloid leukemia with normal Karyotype.
Hematol Oncol stem Cel Ther
1(3): 141-158
Date: 01 2008

The WT1 antigen is a novel target for human CD4+ regulatory T cells: Implications for immunotherapy.
Cancer res
68:(15) 6350-6359
Date: 08 2008

Maternal Acute Lymphocytic Leukemia with Rearrangement of the MIxed Leukemia Gene ocurring during Pregnancy
Hematol Oncol Stem Cell Ther
2(3); 399-402
Date: 01 2009

Molecular Monitoring of response to Imatinib in Chronic Myeloid Leukemia Patients: Experience at a Tertiary Care Hospital in Saudi Arabia
Genetic Testing and Molecular Biomarkers
14(1); 67-74
Date: 02 2010

Modification and Implimentation of NCCN Guidelines on Lymphomas in the Middle East and North Africa Region
J Natl Compr Canc Netw
8 suppl 3; S29-35
Date: 07 2010

High Efficacy and low toxicity of APL Therapy using cocurrent idarubicin/ATRA induction followed by outpatient post remission monthly single doses of idarubicin and intermittent ATRA
Med Oncol
27(3); 702-7
Date: 09 2010